Linkopings universitet, Linkoping, Sweden.
Bioethics. 2019 Feb;33(2):278-286. doi: 10.1111/bioe.12545. Epub 2018 Dec 7.
In healthcare priority settings, early access to treatment before reimbursement decisions gives rise to problems of whether negative decisions for cost-effectiveness reasons should result in withdrawing treatment, already accessed by patients. Among professionals there seems to be a strong attitude to distinguish between withdrawing and withholding treatment, viewing the former as ethically worse. In this article the distinction between withdrawing and withholding treatment for reasons of cost effectiveness is explored by analysing the doing/allowing distinction, different theories of justice, consequentialist and virtue perspectives. The authors do not find any strong reasons for an intrinsic difference, but do find some reasons for a consequentialist difference, given present attitudes. However, overall, such a difference does not, all things considered, provide a convincing reason against withdrawal, given the greater consequentialist gain of using cost-effective treatment. As a result, patients should be properly informed when given early access to treatment, that such treatment can be later withdrawn following a negative reimbursement decision.
在医疗保健的优先设置中,在做出报销决定之前尽早获得治疗会引发一些问题,即出于成本效益原因做出否定决定是否应该导致已经为患者提供的治疗被撤回。在专业人士中,似乎有一种强烈的态度,将撤回和停止治疗区分开来,认为前者在道德上更差。本文通过分析作为/允许的区别、不同的正义理论、后果主义和美德视角,探讨了出于成本效益原因撤回和停止治疗之间的区别。作者没有发现任何内在差异的有力理由,但确实发现了一些基于后果主义的差异的理由,这是基于目前的态度。然而,总的来说,考虑到使用具有成本效益的治疗会带来更大的后果主义收益,这种差异并不能提供一个令人信服的反对撤回的理由。因此,当给予患者早期获得治疗的机会时,应告知患者,在做出否定的报销决定后,这种治疗可能会被撤回。